Kelonia Therapeutics
in vivo CAR-T Pioneer Making Scalable & Accessible Cell Therapies
Key Highlights
- Democratizing CAR-T Therapy: Kelonia’s best-in-class in vivo gene placement system (iGPS) enables the efficient delivery of genetic medicine with high tissue specificity and avoids costly and lengthy ex vivo manufacturing, burdensome lymphodepleting chemotherapy and reliance on large research hospitals
- First-in-human data provides early validation in multiple myeloma: A late-breaking presentation at ASH 2025 shows clinical candidate, KLN-1010, achieved rapid responses in all four patients with a single infusion. Armed with preliminary clinical data and partnerships with multiple pharma companies, Kelonia is positioned well to capitalize on the full potential of its iGPS platform.
- Key Events in 2026: Additional clinical data from Phase 1 trial of KLN-1010, its in vivo CAR-T for multiple myeloma